Navigation Links
Genes Linked to Effectiveness of Tamoxifen for Breast Cancer
Date:12/28/2012

FRIDAY, Dec. 28 (HealthDay News) For breast cancer patients prescribed tamoxifen to treat their disease, genetic traits affecting an enzyme in the liver are major players in determining the impact of the hormone therapy, new research suggests.

There's been debate in the scientific world for years over the role of genetic differences in the enzyme, known as CYP2D6. An estimated 5 percent to 7 percent of European and North American women have a trait that prevents the enzyme from working properly.

"Our findings confirm that, in early breast cancer treated with tamoxifen, genetic alterations in CYP2D6 lead to a higher likelihood of recurrence and death," Dr. Matthew Goetz, a Mayo Clinic oncologist and lead author of the study that reported the findings, said in a Mayo Clinic news release.

The researchers tracked two groups of women: postmenopausal women with primary estrogen receptor-positive breast cancer who received tamoxifen for five years, and those took got the drug for two years followed by another drug, anastrozole, for three years.

Among those who took tamoxifen for five years, those whose genetic makeup prevented the enzyme from being able to process things were 2.5 times more likely to die or have their cancer return than those whose enzymes worked normally, the investigators found.

However, genetic traits involving the enzyme didn't seem to influence the fates of the women who switched to anastrozole, an aromatase inhibitor, after two years of tamoxifen, the study found.

"Switching from tamoxifen to an aromatase inhibitor may be one reason for the discrepant studies surrounding CYP2D6 and tamoxifen -- as information about whether a patient took an aromatase inhibitor after tamoxifen was not available in most of the prior studies," senior author Dr. James Ingle, of the Mayo Clinic, said in the news release.

Goezt thinks the study findings confirm that women should switch from tamoxifen to an aromatase inhibitor, or avoid tamoxifen altogether, if tests show they have the genetic trait that limits the metabolizing process.

The study was released online in advance of publication in an upcoming print issue of the journal Clinical Cancer Research.

More information

For more about breast cancer, visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCE: Mayo Clinic, news release, Dec. 26, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genes Linked to Autism Seem to Have Strong Tendency to Mutate
2. Scientists Now See 200 Genes Linked to Crohns Disease
3. Genes May Influence Effectiveness of Anti-Smoking Policies
4. Ethiopians and Tibetans thrive in thin air using similar physiology, but different genes
5. Valuable tool for predicting pain genes in people
6. A relationship between cancer genes and the reprogramming gene SOX2 discovered
7. Patients with aberrations in two genes respond better to drugs blocking a well-known cancer pathway
8. 1000 genomes study is guidebook to how genes vary
9. New findings on mens genes could alter interpretation of PSA test
10. Scientists step up hunt for bacterial genes tied to Lyme disease
11. Scientists to study the role genes play in treating TB
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genes Linked to Effectiveness of Tamoxifen for Breast Cancer
(Date:4/28/2017)... ... April 28, 2017 , ... Datta ... M.D. has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a ... Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to ... “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa wore his ... of Greater Boston, in a NALA North American Speaker Series (NASS) segment. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... the Brooke Grove Foundation implement a Microsoft Dynamics GP solution that integrates to ... ERP expert that specializes in long-term care, Brooke Grove now has the capability ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation ... Leadership in Neurology Award (PLINA). The couple joins a prestigious list of past ... Walter Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology: